Gimmune GmbH

We sells, distributes and makes three classes of custom tailored products:
  1. Novel compounds which stimulate selective proliferation of human and other mammalian Natural Killer (NK) cells.
  2. Monoclonal antibodies directed against cellular markers for cell differentiation and malignant transformation stages.
  3. Nano and micro scale devices for diagnostics and monitoring of disease/therapy states.
Our R&D activities are devoted to further development of:
  1. Novel drug molecules which can induce selective proliferation of different subsets of NK cell populations in humans.
  2. Complementary therapeutic methods for treating cancer and viral/retroviral infections using NK cells as the “cellular magic bullet”
Information and Marketing Strategy
Gimmune GmbH has exclusive license to sell and distributes:
  1. Novel compounds which stimulate selective proliferation of human and other mammalian Natural Killer (NK) cells. These products and methods are protected by 5 international patents.
  2. Monoclonal antibodies directed against different tumor and/or cell differentiation markers (carcino-embryonal antigens).